medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2025, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2025; 23 (3)

Biologics and JAK inhibitors in atopic dermatitis: a focus on the pediatric population

Aparicio SEE, Gutiérrez ÁSA, Alcántara RVD, Guerrero HDV, García PED, Ojeda MAL, Galván LFB, Trejo OX

Language: Spanish
References: 40
Page: 225-232
PDF size: 187.56 Kb.


ABSTRACT

Atopic dermatitis (AD) is a chronic disease that represents one of the main dermatological conditions today with a strong impact on the pediatric population. For many years, therapies were limited to topical treatments with few options for conventional systemic drugs that, although they provided us with a tool to control the disease, in many cases they did not achieve this goal, significantly impacting quality of life and health. development of pediatric patients. The advent of biological drugs and small molecules in recent years with their activity on specific points of the immune response has made it possible to increase the therapeutic arsenal for those cases refractory to conventional treatment with good clinical results. This review article addresses biological drugs and systemic small molecules that have studies in the pediatric population, their indications, mechanism of action, effectiveness reported in phase III clinical trials, doses and adverse effects.


REFERENCES

  1. Langan SM, Mulick AR, Rutter CE, Silverwood RJ, Asher I, García-Marcos L et al., Trends in eczema prevalence in children andadolescents: a global asthma network phase i study, Clinical &Experimental Allergy 2023; 53(3):337-52.

  2. Faye O, Flohr C, Kabashima K, Ma L, Paller AS, Rapelanoro FRet al., Atopic dermatitis: a global health perspective, J Eur AcadDermatol Venereol 2024; 38(5):801-11.

  3. Weidinger S, Beck LA, Bieber T, Kabashima K y Irvine AD, Atopicdermatitis, Nat Rev Dis Primers 2018; 4(1):1.

  4. Boothe WD, Tarbox JA y Tarbox MB, Atopic dermatitis: pathophysiology,Adv Exp Med Biol 2017; 1027:21-37.

  5. Schneider S, Li L y Zink A, The new era of biologics in atopic dermatitis:a review, Dermatol Pract Concept 2021; 11(4):e2021144.

  6. Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De BenedettoA, Ellison K et al., Atopic dermatitis (eczema) guidelines:2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology JointTask Force on Practice Parameters grade –and Institute of Medicine–based recommendations, Ann Allergy Asthma Immunol2024; 132(3):274-312.

  7. Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE,Darr JM et al., Guidelines of care for the management of atopicdermatitis in adults with phototherapy and systemic therapies,J Am Acad Dermatol 2024; 90(2):e43-56.

  8. Larenas D, Rincón C, Luna J, Weinmann A, Vidaurri H, NavarreteE et al., Guidelines on atopic dermatitis for Mexico (GuidaMex):using the adapte methodology, Gac Med Mex 2023; 158.

  9. Seegräber M, Srour J, Walter A, Knop M, Wollenberg A, Dupilumabfor treatment of atopic dermatitis, Expert Rev Clin Pharmacol2018; 11(5):467-74.

  10. Waligóra K, Dan´czak A y Jenerowicz D, Comprehensive reviewof biologics in phase iii and iv clinical trials for atopic dermatitis,J Clin Med 2024; 13(14):4001.

  11. Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, ChenIH et al., Dupilumab safety and efficacy up to 1 year in childrenaged 6 months to 5 years with atopic dermatitis: results from aphase 3 open-label extension study, Am J Clin Dermatol 2024;25(4):655-68.

  12. Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, ArkwrightPD et al., Efficacy and safety of dupilumab with concomitanttopical corticosteroids in children 6 to 11 years old with severeatopic dermatitis: a randomized, double-blinded, placebo-controlledphase 3 trial, J Am Acad Dermatol 2020; 83(5):1282-93.

  13. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L,Gooderham MJ et al., Efficacy and safety of dupilumab in adolescentswith uncontrolled moderate to severe atopic dermatitis:a phase 3 randomized clinical trial, jama Dermatol 2020;156(1):44.

  14. Baselga E, Ramien M, Marcoux D, De Graaf M, Irvine AD, CarvalhoVO et al., Dupilumab improves disease severity in childrenless than 12 years of age with moderate-severe ad: interim resultsfrom pedistad real-world registry, British Journal of Dermatology2024; 190(Suppl2):ii13-4.

  15. Wang M, Gao XH y Zhang L, A review of dupilumab in the treatmentof atopic dermatitis in infants and children, Drug Des DevelTher 2024; 18:941-51.

  16. Bettuzzi T, Drucker A, Staumont-Sallé D, Bihan K, Lebrun-VignesB y Sbidian E, Adverse events associated with dupilumab in theWorld Health Organization pharmacovigilance database, J AmAcad Dermatol 2022; 86(2):431-3.

  17. Gonçalves F, Freitas E y Torres T, Selective il-13 inhibitors forthe treatment of atopic dermatitis, Drugs Context 2021; 10:1-7.

  18. Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC et al.,Efficacy and safety of tralokinumab in adolescents with moderateto severe atopic dermatitis: the phase 3 ecztra 6 randomizedclinical trial, jama Dermatol 2023; 159(6):596-605.

  19. George A, Lansang RP, Lansang P y Gooderham M, A practicalguide to using biologics in pediatric dermatology, J Cutan MedSurg 2024; 28(1):59-67.

  20. Bernardo D, Bieber T y Torres T, Lebrikizumab for the treatmentof moderate-to-severe atopic dermatitis, Am J Clin Dermatol2023; 24(5):753-64.

  21. Silverberg JI, Guttman E, Thaçi D, Irvine AD, Stein Gold L, BlauveltA et al., Two phase 3 trials of lebrikizumab for moderate-tosevereatopic dermatitis, N Engl J Med 2023; 388(12):1080-91.

  22. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, ArmstrongA, Soung J et al., Efficacy and safety of lebrikizumab incombination with topical corticosteroids in adolescents andadults with moderate-to-severe atopic dermatitis: a randomizedclinical trial (adhere), jama Dermatol 2023; 159(2):182.

  23. Serra-Baldrich E, Santamaría-Babí LF y Francisco Silvestre J, Nemolizumab:un innovador tratamiento biológico para el controlde la interleuquina 31 (il-31) clave en la dermatitis atópica y elprurigo nodular, Actas Dermosifiliogr 2022; 113(7):674-84.

  24. Kabashima K, Matsumura T, Komazaki H y Kawashima M,Nemolizumab plus topical agents in patients with atopic dermatitis(ad) and moderate-to-severe pruritus provide improvementin pruritus and signs of ad for up to 68 weeks: resultsfrom two phase iii, long-term studies, Br J Dermatol 2022;186(4):642-51.

  25. Liang J, Hu F, Dan M, Sang Y, Abulikemu K, Wang Q et al., Safetyand efficacy of nemolizumab for atopic dermatitis with pruritus:a systematic review and meta-regression analysis of randomizedcontrolled trials, Front Immunol 2022; 13:825312.

  26. Kabashima K, Matsumura T, Hayakawa Y y Kawashima M, Clinicallymeaningful improvements in cutaneous lesions and qualityof life measures in patients with atopic dermatitis with greaterpruritus reductions after treatment with 60 mg nemolizumabsubcutaneously every 4 weeks: subgroup analysis from aphase 3, randomized, controlled trial, J Dermatolog Treat 2023;34(1):2177096.

  27. Igarashi A, Katsunuma T, Matsumura T y Komazaki H, Efficacyand safety of nemolizumab in paediatric patients aged 6-12years with atopic dermatitis with moderate-to-severe pruritus:results from a phase iii, randomized, double-blind, placebocontrolled,multicentre study, Br J Dermatol 2023; 190(1):20-8.

  28. Keam SJ, Nemolizumab: first approval, Drugs 2022; 82(10):1143-50.

  29. García C, Cubiró X y Puig L, Janus kinase inhibitors in dermatology.Part 1: general considerations and applications in vitiligoand alopecia areata, Actas Dermosifiliogr 2024; 112(6):503-515.

  30. García C, Cubiró X y Puig L, Janus kinase inhibitors in dermatology.Part 2: applications in psoriasis, atopic dermatitis, andother dermatoses, Actas Dermosifilio 2021; 112(7):586-600.

  31. Klein B, Treudler R y Simon JC, jak –inhibitors in dermatology–small molecules, big impact? Overview of the mechanism ofaction, previous study results and potential adverse effects, JDtsch Dermatol Ges 2022; 20(1):19-24.

  32. Mohamed FM, Bhatnagar S, Parmentier JM, Nakasato P yWung P, Upadacitinib: mechanism of action, clinical, and translationalscience, Clin Transl Sci 2024; 17(1):e13688.

  33. Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N etal., Efficacy and safety of upadacitinib in patients with moderateto severe atopic dermatitis: analysis of follow-up data from themeasure up 1 and measure up 2 randomized clinical trials, jamaDermatol 2022; 158(4):404-13.

  34. Paller AS, Ladizinski B, Mendes P, Siegfried E, Soong W y PrajapatiV, Efficacy and safety of upadacitinib treatment in adolescentswith moderate-to-severe atopic dermatitis: analysis ofthe measure up 1, measure up 2, and ad up randomized clinicaltrials, jama Dermatol 2023; 159(5):526-35.

  35. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-WellerM, Barbarot S et al., Efficacy and safety of upadacitinib vsdupilumab in adults with moderate-to-severe atopic dermatitis:a randomized clinical trial, jama Dermatol 2021; 157(9):1047-55.

  36. Guttman E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, WeidingerS et al., Safety of upadacitinib in moderate-to-severeatopic dermatitis: an integrated analysis of phase 3 studies, JAllergy Clin Immunol 2023; 151(1):172-81.

  37. Hoy SM, Baricitinib: a review in moderate to severe atopic dermatitis,Am J Clin Dermatol 2022; 23(3):409-20.

  38. Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, PrakashA et al., Efficacy and safety of baricitinib in combination withtopical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response totopical corticosteroids: results from a phase iii, randomized,double-blind, placebo-controlled study (breeze-ad peds), Br JDermatol 2023; 189(1):23-32.

  39. Deeks ED y Duggan S, Abrocitinib: first approval. Drugs 2021;81(18):2149-57.

  40. Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, GalusR et al., Efficacy and safety of abrocitinib in combination withtopical therapy in adolescents with moderate-to-severe atopicdermatitis, jama Dermatol 2021; 157(10):1-9.




2020     |     www.medigraphic.com